| Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivopurged stem cell rescue: a nonrandomized phase 2
CH Geisler, A Kolstad, A Laurell, NS Andersen, LB Pedersen, ... Blood, The Journal of the American Society of Hematology 112 (7), 2687-2693, 2008 | 730 | 2008 |
| Treatment of older patients with mantle-cell lymphoma HC Kluin-Nelemans, E Hoster, O Hermine, J Walewski, M Trneny, ... New England Journal of Medicine 367 (6), 520-531, 2012 | 605 | 2012 |
| Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic
T Robak, A Dmoszynska, P Solal-Céligny, K Warzocha, J Loscertales, ... Journal of clinical oncology 28 (10), 1756-1765, 2010 | 603 | 2010 |
| An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data International CLL-IPI Working Group The Lancet Oncology 17 (6), 779-790, 2016 | 571 | 2016 |
| Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies A Agathangelidis, N Darzentas, A Hadzidimitriou, X Brochet, F Murray, ... Blood, The Journal of the American Society of Hematology 119 (19), 4467-4475, 2012 | 487 | 2012 |
| Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial MZH Farooqui, J Valdez, S Martyr, G Aue, N Saba, CU Niemann, ... The lancet oncology 16 (2), 169-176, 2015 | 466 | 2015 |
| TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy CW Eskelund, C Dahl, JW Hansen, M Westman, A Kolstad, LB Pedersen, ... Blood, The Journal of the American Society of Hematology 130 (17), 1903-1910, 2017 | 319 | 2017 |
| Nordic MCL 2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+ autologous stem‐cell support
CH Geisler, A Kolstad, A Laurell, M Jerkeman, R Räty, NS Andersen, ... British journal of haematology 158 (3), 355-362, 2012 | 313 | 2012 |
| The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated proteinkinasedependent mechanism IM Pedersen, AM Buhl, P Klausen, CH Geisler, J Jurlander Blood, The Journal of the American Society of Hematology 99 (4), 1314-1319, 2002 | 311 | 2002 |
| Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia CH Geisler, JK Larsen, NE Hansen, MM Hansen, BE Christensen, B Lund, ... | 245 | 1991 |
| ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) M Ghielmini, U Vitolo, E Kimby, S Montoto, J Walewski, M Pfreundschuh, ... Annals of oncology 24 (3), 561-576, 2013 | 236 | 2013 |
| Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials CLL Trialists' CollaborativeGroup Journal of the National Cancer Institute 91 (10), 861-868, 1999 | 235 | 1999 |
| Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study SEM Herman, CU Niemann, M Farooqui, J Jones, RZ Mustafa, A Lipsky, ... Leukemia 28 (11), 2188-2196, 2014 | 211 | 2014 |
| Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study IE Ahn, MZH Farooqui, X Tian, J Valdez, C Sun, S Soto, J Lotter, S Housel, ... Blood, The Journal of the American Society of Hematology 131 (21), 2357-2366, 2018 | 207 | 2018 |
| 15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (MCL 2): prolonged remissions without survival plateau CW Eskelund, A Kolstad, M Jerkeman, R Räty, A Laurell, S Eloranta, ... British journal of haematology 175 (3), 410-418, 2016 | 207 | 2016 |
| Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases A Hadzidimitriou, A Agathangelidis, N Darzentas, F Murray, ... Blood, The Journal of the American Society of Hematology 118 (11), 3088-3095, 2011 | 203 | 2011 |
| The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line
CH Geisler, A Kolstad, A Laurell, R Räty, M Jerkeman, M Eriksson, ... Blood, The Journal of the American Society of Hematology 115 (8), 1530-1533, 2010 | 199 | 2010 |
| Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study F Pandolfi, TP Loughran Jr, G Starkebaum, T Chisesi, T Barbui, WC Chan, ... Cancer 65 (2), 341-348, 1990 | 186 | 1990 |
| Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network E Hoster, W Klapper, O Hermine, HC Kluin-Nelemans, J Walewski, ... J Clin Oncol 32 (13), 1338-1346, 2014 | 183 | 2014 |
| Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up M Dreyling, C Geisler, O Hermine, HC Kluin-Nelemans, S Le Gouill, ... Annals of Oncology 25, iii83-iii92, 2014 | 169 | 2014 |
